Skip to main content
NCBI home page
Journal of Ginseng Research logoLink to Journal of Ginseng Research
. 2015 Jan 10;39(3):230–237. doi: 10.1016/j.jgr.2014.12.004

American ginseng significantly reduced the progression of high-fat-diet-enhanced colon carcinogenesis in ApcMin/+mice

Chunhao Yu 1,2,3,4,☆, Xiao-Dong Wen 3,4,☆, Zhiyu Zhang 3,4, Chun-Feng Zhang 3,4, Xiaohui Wu 3,4, Xin He 3,4, Yang Liao 3,5, Ningning Wu 3,6, Chong-Zhi Wang 3,4, Wei Du 3,5, Tong-Chuan He 3,6, Chun-Su Yuan 3,4,7,∗
PMCID: PMC4506368  PMID: 26199554

Abstract

Background

Colorectal cancer (CRC) is a leading cause of death worldwide. Chronic gut inflammation is recognized as a risk factor for tumor development, including CRC. American ginseng is a very commonly used ginseng species in the West.

Methods

A genetically engineered ApcMin/+ mouse model was used in this study. We analyzed the saponin composition of American ginseng used in this project, and evaluated its effects on the progression of high-fat-diet-enhanced CRC carcinogenesis.

Results

After oral ginseng administration (10–20 mg/kg/d for up to 32 wk), experimental data showed that, compared with the untreated mice, ginseng very significantly reduced tumor initiation and progression in both the small intestine (including the proximal end, middle end, and distal end) and the colon (all p < 0.01). This tumor number reduction was more obvious in those mice treated with a low dose of ginseng. The tumor multiplicity data were supported by body weight changes and gut tissue histology examinations. In addition, quantitative real-time polymerase chain reaction analysis showed that compared with the untreated group, ginseng very significantly reduced the gene expression of inflammatory cytokines, including interleukin-1α (IL-1α), IL-1β, IL-6, tumor necrosis factor-α, granulocyte-colony stimulating factor, and granulocyte-macrophage colony-stimulating factor in both the small intestine and the colon (all p < 0.01).

Conclusion

Further studies are needed to link our observed effects to the actions of the gut microbiome in converting the parent ginsenosides to bioactive ginseng metabolites. Our data suggest that American ginseng may have potential value in CRC chemoprevention.

Keywords: ApcMin/+mice, colorectal cancer, ginsenoside metabolites, inflammatory cytokines, Panax quinquefolius L.

1. Introduction

Colorectal cancer (CRC) is a leading cause of patients' morbidity and mortality. In 2014 alone, there were an estimated 136,830 new CRC cases and 50,310 CRC-related deaths in the United States [1,2]. A significant number of men and women worldwide are at risk of developing invasive CRC in their lifetime [3]. Because currently available therapies for advanced CRC have limited efficacy, increased attention has been focused on CRC prevention.

Using Asian ginseng, a case–control study on over a thousand participants in Korea showed that participants who consumed ginseng had a decreased risk of many different cancers compared with those who did not. In addition, ginseng has a nonorgan-specific cancer prevention effect [4,5]. In contrast to Asian ginseng [5–7], however, the effects of American ginseng on CRC therapeutics have not been evaluated.

Chronic inflammation is recognized as a risk factor for tumor development, including CRC [8–10]. There is growing evidence to support the efficacy of natural products possessing anti-inflammatory activities. Published studies suggested that ginseng not only has cancer prevention potential [4,5,11,12], but also has anti-inflammatory effects [13,14]. Various data suggest that ginseng reduces inflammation and suppresses colitis by restoring gut homeostasis [15–17], and this anti-inflammatory activity likely plays a critical role in cancer prevention and treatment [18–20].

American ginseng (Panax quinquefolius L.) is one of the most commonly used herbal medicines in the United States [21,22]. Similar to Asian ginseng, a significant number of ginsenosides have been identified in American ginseng. These ginsenosides fall into two major groups: the protopanaxadiol group and the protopanaxatriol group, which differ in the presence of the carboxyl group at the C-6 position [21,23]. However, the ginsenoside profile between American ginseng and Asian ginseng is different, and this difference may contribute to their different pharmacological effects. Interestingly, American ginseng has approximately over onefold higher ginsenoside content than Asian ginseng [21,24,25]. In addition to ginsenosides, ginseng also contains other bioactive compounds [21,24].

Significant antitumor effects of American ginseng were observed in the CRC cell-xenografted nude mouse model [26,27]. However, the nude mouse is not a gut disease-specific animal model. Thus, it is desirable to use specific gut inflammatory and malignancy animal models. In this study, we used ApcMin/+ mice, an animal model with mutations in the Apc gene. This multiple intestinal neoplasia (Min) mouse is characterized by early lethality, colon tumors, and development of a number of polyps in the small intestine [28–30]. Our data demonstrated that American ginseng significantly reduced the progression of high-fat-diet-enhanced carcinogenesis in this ApcMin/+mouse model.

2. Materials and methods

2.1. Chemicals and reagents

High-performance liquid chromatography (HPLC)-grade ethanol, n-butanol, acetonitrile, and dimethyl sulfoxide were purchased from Fisher Scientific (Pittsburgh, PA, USA). Milli-Q water was supplied by a water purification system (US Filter, Palm Desert, CA, USA). Standards of ginsenosides Rb1, Rb2, Rb3, Rc, Rd, Re, Rf, Rg1, Rg2, 20R-Rg2, Rg3, Rh1, and Rh2 were obtained from INDOFINE Chemical Company (Somerville, NJ, USA) or Delta Information Center for Natural Organic Compounds (Xuancheng, Anhui, China). All standards were of biochemical-reagent grade and at least 95% pure. Other reagents were of biochemical-reagent grade.

2.2. Botanical material and preparation

The 4-year-old roots of American ginseng (P. quinquefolius L.) were purchased from Roland Ginseng, LLC (Wausau, WI, USA). The voucher samples were authenticated by C.-Z.W. and deposited at the Tang Center for Herbal Medicine Research at the University of Chicago (Chicago, IL, USA). The American ginseng extract was prepared with a slight modification from previous works [31–33]. The air-dried roots of American ginseng were pulverized into powder form and sieved through an 80-mesh screen. One kilogram of the powder was placed into a 12-L flask and extracted three times by heat reflux with 8 L of 75% (v/v) ethanol at 95°C for 4 h each time. The extracting solution was filtered while hot. The gathered and combined filtrate was evaporated under vacuum with a Buchi rotary evaporator (Buchi Corporation, New Castle, DE, USA). The obtained extract was dissolved in water, and then extracted with water-saturated n-butanol. The n-butanol phase was evaporated at 65°C under vacuum and lyophilized.

2.3. Phytochemical analysis

The American ginseng extract was analyzed using HPLC [34,35]. The HPLC system used was a Waters Alliance 2960 instrument (Milford, MA, USA) with a quaternary pump, an automatic injector, a photodiode array detector (Model 996), and Waters Millennium 32 software for peak identification and integration. The separation was carried out on a Prodigy ODS2 column (250 mm × 3.2 mm i.d.; Phenomenex, Torrance, CA, USA) with a guard column (Prodigy, 3.0 mm × 4.0 mm i.d.; Phenomenex).

For the HPLC analysis, a 20-μL sample was injected into the column and eluted at room temperature with a constant flow rate of 1.0 mL/min. For the mobile phase, acetonitrile (Solvent A) and water (Solvent B) were used. Gradient elution started with 17.5% Solvent A and 82.5% Solvent B. Elution solvents were then changed to 21% Solvent A for 20 min, then to 26% Solvent A for 3 min and held for 19 min, maintained at 36% Solvent A for 13 min, at 50% Solvent A for 9 min, at 95% Solvent A for 2 min and held for 3 min. Finally, eluting solvents were changed to 17.5% Solvent A for 3 min and held for 8 min. The detection wavelength was set at 202 nm. All sample solutions were filtered through a membrane filter (0.2-μm pore size). The content of the constituents was calculated using standard curves of the ginsenosides. The contents of American ginseng were measured in triplicate. Malonyl ginsenosides were not measured in this investigation.

2.4. Animals and experimental protocol

The experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Chicago. Male C57BL/6J-ApcMin/J and female C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA) for breeding. Mice were caged under controlled room temperature, humidity, and light (12/12-h light/dark cycle) and had free access to mouse chow and tap water. After weaning, genotyping was carried out by tail biopsy using PCR-based assays to identify ApcMin/+mice [28].

The study protocol is shown in Fig. 1. There were six animal groups (n = 6–9 animals/group). Prior to 6 wk of age, all mice consumed standard mouse chow. The ApcMin/+ mice were randomized at 6 wk of age and placed into the following experimental groups: (1) mice that received Western high-fat diet were categorized as the model group (M-HF); (2) mice that received standard diet as the control group (M-SD); (3) mice that received Western high-fat diet supplemented with 200 ppm of the American ginseng extract, equivalent to 20 mg/kg/d, as the high-dose ginseng group (M-GH); (4) mice that received Western high-fat diet supplemented with 100 ppm of the American ginseng extract, equivalent to 10 mg/kg/d, as the low-dose ginseng group (M-GL). As the control or negative control group, two wild-type mice groups were used: (1) wild-type mice fed with standard diet (wild-type standard diet control group, or W-SD); (2) wild-type mice fed with Western high-fat diet (wild-type high-fat-diet control group, or W-HF). The Western diet (Harlan Laboratories, Madison, WI, USA) contains 20% fat and includes beef tallow (35 g/kg), lard (30 g/kg), and corn oil (80 g/kg) [36]. Body weight of the animals was obtained at least once per wk. No significant adverse events were observed in the mice after the ginseng treatment.

Fig. 1.

Fig. 1

Open in a new tab

Experimental groups and study time lines. Prior to the age of 6 wk, all mice consumed standard mouse chow. The six experimental groups (n = 6–9 animals/group) are as follows: (1) M-HF, mice fed with Western high-fat diet as the model group; (2) M-SD, mice fed with standard diet as the control group; (3) M-GH, mice fed with Western diet supplemented with high-dose American ginseng extract; (4) M-GL, mice fed with Western diet supplemented with low-dose American ginseng extract; (5) W-SD, wild-type mice fed with standard diet; and (6) W-HF, wild-type mice fed with Western high-fat diet. Study protocols are presented in the “Materials and methods” section.

At the end of each observation period, samples of small intestine and colon were harvested, flushed immediately with ice-cold phosphate-buffered saline, and slit open longitudinally. Under a dissection microscope, tumor numbers in the proximal, middle, and distal ends of the small intestine and the colon were counted by two independent investigators who were blinded with respect to the treatment group. Small intestinal and colon samples were fixed in 10% neutral-buffered formalin, embedded in paraffin blocks, and processed by routine histological staining. Some colon tissue was collected for quantitative real-time polymerase chain reaction (qRT-PCR) analysis of interleukin-1α (IL-1α), IL-1β, IL-6, tumor necrosis factor (TNF-α), granulocyte-colony stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF).

2.5. Histological assessment

Paraffin-embedded tissue samples were serially sectioned, and some of these sections were stained with hematoxylin and eosin. The stained sections were subsequently examined for histopathological changes by a gastrointestinal pathologist.

2.6. RNA extraction and qRT-PCR

Total RNA was isolated from the mouse colonic tissues using the miRNeasy kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions and was used as a template to synthesize complementary DNA for qRT-PCR. First-strand cDNA was synthesized using Thermo Scientific Maxima first-strand cDNA synthesis kit. RT-qPCR was performed on a real-time PCR system (7900HT; Applied Biosystems, Foster City, CA, USA). RT-qPCR with SYBR Green dye (Qiagen) was used to determine the expression of genes. Primers for RT-qPCR are presented in Table 1. β actin was used as the endogenous control. Each sample was run in triplicate.

Table 1.

Primers used for RT-qPCR analysis of inflammatory cytokines

Gene Primer Sequence
IL1α Forward primer 5′-CGAAGACTACAGTTCTGCCATT-3′
Reverse primer 5e-GACGTTTCAGAGGTTCTCAGAG-3G
IL1β Forward primer 5o-GCAACTGTTCCTGAACTCAACT-3G
Reverse primer 5e-ATCTTTTGGGGTCCGTCAACT-3A
IL6 Forward primer 5o-TAGTCCTTCCTACCCCAATTTCC-3T
Reverse primer 5e-TTGGTCCTTAGCCACTCCTTC-3T
IFN-γ Forward primer 5o-ATGAACGCTACACACTGCATC-3A
Reverse primer 5e-CCATCCTTTTGCCAGTTCCTC-3C
G-CSF Forward primer 5o-ATGGCTCAACTTTCTGCCCAG-3A
Reverse primer 5e-CTGACAGTGACCAGGGGAAC-3C
GM-CSF Forward primer 5o-GGCCTTGGAAGCATGTAGAGG-3G
Reverse primer 5e-GGAGAACTCGTTAGAGACGACTT-3G
β-actin Forward primer 5o-GGCTGTATTCCCCTCCATCG-3G
Reverse primer 5e-CCAGTTGGTAACAATGCCATGT-3C
Open in a new tab

RT-qPCR, quantitative real-time polymerase chain reaction

2.7. Statistical analysis

Data were presented as mean ± standard deviation. Data were analyzed using analysis of variance for repeated measures and Student t test. All analyses were performed using SPSS version 14.0 (IBM Corporation, Somers, NY, USA). The level of statistical significance was set at p < 0.05.

3. Results

3.1. Saponin composition in the study samples

Fig. 2A shows the chemical structures of ginsenosides in both the protopanaxadiol and protopanaxatriol groups in the American ginseng root. A typical HPLC chromatogram of the ginseng extract is shown in Fig. 2B. The levels of the measured 11 ginsenosides are presented in Fig. 2C. The major constituents of the protopanaxatriol group are Re, followed by Rg1. More than 70% of the ginsenosides are in the protopanaxadiol group, including Rb1, Rd, Rc, Rb3, and Rb2. Unlike in Asian ginseng, no ginsenoside Rf was detected in American ginseng.

Fig. 2.

Fig. 2

Open in a new tab

Major ginsenosides in American ginseng (Panax quinquefolius). (A) Chemical structures of ginsenosides in both the protopanaxadiol and protopanaxatriol groups. (B) A representative high-performance liquid chromatography chromatogram of the American ginseng extract. (C) Levels of the measured 11 ginsenosides.

3.2. Body weight changes

The body weight changes of the animals in different experimental groups are shown in Fig. 3. Wild-type mice with standard diet had an approximate weight increase of 12 g over the 10-wk observation period. As expected, those wild-type mice fed with Western high-fat diet had an even higher weight increase of approximately 17 g. However, the ApcMin/+ mice in the model group did not respond to the high-fat diet well, and their weight only increased slightly. For the model group mice, the body weight started to decrease from Wk 10, and all mice died on or prior to Wk 18. By contrast, the ApcMin/+ mice with standard diet had obvious weight gain (∼ 13 g), suggesting that the high-fat diet effectively caused some pathological changes in the ApcMin/+ mice. High-dose American ginseng showed some small increase in body weight. Interestingly, low-dose American ginseng perceptibly increased body weight, suggesting the reduced pathological problems. The low-dose American ginseng data were consistent with the gut histology and tumor multiplicity data presented in the following section.

Fig. 3.

Fig. 3

Open in a new tab

Changes in animal body weight. As discussed in the text, the ApcMin/+ mice received low-dose American ginseng in this study, which appeared to have evident therapeutic effects. The six experimental groups (n = 6–9 animals/group) are as follows: (1) M-HF, mice fed with Western high-fat diet as the model group; (2) M-SD, mice fed with standard diet as the control group; (3) M-GH, mice fed with Western diet supplemented with high-dose American ginseng extract; (4) M-GL, mice fed with Western diet supplemented with low-dose American ginseng extract; (5) W-SD, wild-type mice fed with standard diet; and (6) W-HF, wild-type mice fed with Western high-fat diet. Study protocols are presented in the “Materials and methods” section.

3.3. Gut histopathology changes

Fig. 4 shows the representative hematoxylin and eosin staining histological sections of experimental animals with different treatments. Histological analysis of the tissues from the model group showed prominent adenomatous change along with inflammatory lesions, such as some neutrophil infiltration. Focal adenomatous change can also be seen in the ApcMin/+ mice with standard diet. However, in the ginseng-treated groups, especially the low-dose ginseng group, the dysplastic changes were greatly reduced in both small intestine and colon slides.

Fig. 4.

Fig. 4

Open in a new tab

Effects of American ginseng on the histological characterization in ApcMin/+ mice. Representative hematoxylin and eosin staining histological sections showing inflammatory changes in (A) the small intestine and (B) the colon with different treatments. The scale in the low right figure is 200μM. Arrowheads indicate inflammation lesions in the gut tissue. The six experimental groups (n = 6–9 animals/group) are as follows: (1) M-HF, mice fed with Western high-fat diet as the model group; (2) M-SD, mice fed with standard diet as the control group; (3) M-GH, mice fed with Western diet supplemented with high-dose American ginseng extract; (4) M-GL, mice fed with Western diet supplemented with low-dose American ginseng extract; (5) W-SD, wild-type mice fed with standard diet; and (6) W-HF, wild-type mice fed with Western high-fat diet. Study protocols are presented in the “Materials and methods” section.

3.4. Tumor multiplicity changes

Compared with the high-fat diet, APCmin/+mice that received standard diet had reduced tumor numbers. After treatment with American ginseng, the tumor numbers were very significantly reduced in both the small intestine (including the proximal, middle, and distal ends) and the colon (all p < 0.01). In addition, tumor number reduction was more obvious in those mice treated with low-dose American ginseng (Fig. 5).

Fig. 5.

Fig. 5

Open in a new tab

Effects of American ginseng on gut carcinogenesis. (A) Macroscopic view of representative gut samples from the small intestine and the colon. (B) American ginseng significantly reduces the tumor numbers in the different gut segments. Tumors in the gut tissue are indicated by arrowheads (**p < 0.01 compared with the model group). The six experimental groups (n = 6–9 animals/group) are as follows: (1) M-HF, mice fed with Western high-fat diet as the model group; (2) M-SD, mice fed with standard diet as the control group; (3) M-GH, mice fed with Western diet supplemented with high-dose American ginseng extract; (4) M-GL, mice fed with Western diet supplemented with low-dose American ginseng extract; (5) W-SD, wild-type mice fed with standard diet; and (6) W-HF, wild-type mice fed with Western high-fat diet. Study protocols are presented in the “Materials and methods” section.

3.5. qRT-PCR analysis

Fig. 6 shows the qRT-PCR analysis of IL-1α, IL-1β, IL-6, TNF-α, G-CSF, and GM-CSF levels in the tissue obtained from the model group and the American ginseng groups. The results of the analysis indicated that low-dose American ginseng had better activities in the small intestine. Only low-dose ginseng was used in colon samples because this dose was more effective in the small intestine (Figs. 6A, 6B).

Fig. 6.

Fig. 6

Open in a new tab

Quantitative real-time polymerase chain reaction analysis of IL-1α, IL-1β, IL-6, IFN-g, G-CSF, and GM-CSF in the gut tissue from the model group and the American ginseng groups. (A) Small intestine. (B) Colon. Only low-dose ginseng is used in colon samples because this dose is more effective in the small intestine. *p < 0.01 compared with the model group. The six experimental groups (n = 6–9 animals/group) are as follows: (1) M-HF, mice fed with Western high-fat diet as the model group; (2) M-SD, mice fed with standard diet as the control group; (3) M-GH, mice fed with Western diet supplemented with high-dose American ginseng extract; (4) M-GL, mice fed with Western diet supplemented with low-dose American ginseng extract; (5) W-SD, wild-type mice fed with standard diet; and (6) W-HF, wild-type mice fed with Western high-fat diet. Study protocols are presented in the “Materials and methods” section. G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin.

4. Discussion

Inflammatory bowel disease is a group of inflammatory conditions in the large and small intestine in humans. Inflammation can initiate and promote stimuli and mediators, generating a tumor-prone microenvironment. Chronic inflammation is recognized as a risk factor for tumor development, including CRC [8–10]. Targeting inflammatory pathways has been shown to be effective in preventing the formation of colon tumors and their malignant progression in both animal and human studies [37]. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce CRC tumorigenesis, but concerns and long-term risks of NSAIDs make this form of prevention unsuitable as a general recommendation [38,39]. Given the limitations of today's clinical practice, there is a strong motivation for exploring alternative strategies, including using herbal medicines, in the management of malignancies in the gastrointestinal system [40–43].

To evaluate the pharmacological effects on gut inflammation and tumorigenesis, two gut-specific animal models have been used in this study, namely, the AOM/DSS and ApcMin/+ mice. AOM/DSS is a chemical-compound-induced model, characterized by early inflammation followed by tumor development [44,45]. This chemically induced murine model has been used for inflammation-related colon carcinogenesis in the last decade. To further characterize the activities of American ginseng, we used a genetically engineered mouse model that has a mutation in the Apc gene resulting in the growth of small intestine polyps and colon tumors associated with inflammation [46,47]. The association of inflammation with tumorigenesis in the ApcMin/+ mouse model has been reported [46]. For example, celecoxib, a cyclooxygenase-2 inhibitor that belongs to the NSAID family, has been reported to possess potent preventive and therapeutic effects in ApcMin/+ mice [47].

In our study, we demonstrated that low oral dose of American ginseng significantly reduced the progression of high-fat-diet-enhanced carcinogenesis in ApcMin/+ mice. qRT-PCR analysis data showed that compared with the model group, ginseng, especially at low doses, very significantly reduced the gene expression inflammation cytokines, such as IL-1α, IL-1β, IL-6, TNF-α, G-CSF, and GM-CSF in the tissue from both the small intestine and the colon. The qRT-PCR results were consistent with survival, tumor growth inhibition, and histology data.

As with many other herbal medicines, American ginseng is almost always taken orally. Unlike parenteral administration that has been used in many animal studies, the enteric microbiome likely plays an important role after the oral intake of ginseng [29,36,37,48]. When ingested orally, the bioavailability of ginseng is low due to incomplete absorption of parent compound and the conversion of parent ginsenosides to bioactive ginseng metabolites by the enteric microbiome that involves a stepwise cleavage of sugar moieties [33,49,50]. After ginseng ingestion, compound K and protopanaxadiol are the major metabolites that reach systemic circulation, and these metabolites likely possess significant anti-inflammatory and anticancer properties [26,51]. At the same time, ginseng and its metabolites may alter the structure of the enteric microbiome. The conversion of ginseng saponins by human enteric microbiome was recently demonstrated, with > 20 metabolites detected [33]. In our ongoing investigations, ginseng metabolites in various biological samples (plasma, bile, urine, and stool) are being analyzed using ultraperformance liquid chromatography with quadruple time-of-flight mass spectrometry. In addition to compound K and protopanaxadiol, other ginseng metabolites should be searched, which may have even stronger bioactivities [26,52]. Further, other compounds identified in ginseng, such as polyacetylenes [24], are likely to have pharmacological activities, and they should also be evaluated in future studies.

In summary, using a gut-specific inflammation and carcinogenesis ApcMin/+mouse model, we reported that a low oral dose of American ginseng significantly reduced gut inflammation and tumor initiation and progression. The observed effects were supported by the body weight change, gut tissue histology, and gut inflammation cytokine data. Further studies are needed to link our observed effects to the actions of the gut microbiome in converting the parent ginsenosides to bioactive ginseng metabolites. Our data suggest that American ginseng may have a therapeutic role in CRC chemoprevention.

Conflicts of interest

All contributing authors declare no conflicts of interest.

Acknowledgments

This work was supported in part by grants from the National Institutes of Health/National Center for Complementary and Integrative Health, formerly National Center for Complementary and Alternative Medicine (Grant Nos. AT004418 and AT005362), the National Science Foundation of China (Grant No. 30973884), the Natural Science Foundation of Jiangsu Province (Grant No. BK2008194), and the Science and Technology Project of the Department of Traditional Chinese Medicines in Jiangsu Province (Grant No. LZ11163).

Footnotes

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

  • 1.National Cancer Institute . NCI; Bethesda (MD): 2014. Colon and rectal cancer.http://www.cancer.gov/cancertopics/types/colon-and-rectal [Internet] [cited 2014 Jun 2] Available from: [Google Scholar]
  • 2.Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–117. doi: 10.3322/caac.21220. [DOI] [PubMed] [Google Scholar]
  • 3.National Cancer Institute . NCI; Bethesda (MD): 2014. SEER stat fact sheets: colon and rectum.http://seer.cancer.gov/statfacts/html/colorect.html#risk [Internet] [cited 2014 Jun 2] Available from: [Google Scholar]
  • 4.Yun T.K., Choi S.Y. Preventive effect of ginseng intake against various human cancers: a case-control study on 1987 pairs. Cancer Epidemiol Biomarkers Prev. 1995;4:401–408. [PubMed] [Google Scholar]
  • 5.Yun T.K. Panax ginseng—a non-organ-specific cancer preventive? Lancet Oncol. 2001;2:49–55. doi: 10.1016/S1470-2045(00)00196-0. [DOI] [PubMed] [Google Scholar]
  • 6.Gu C., Qiao J., Zhu M., Du J., Shang W., Yin W., Wang W., Han M., Lu W. Preliminary evaluation of the interactions of Panax ginseng and Salvia miltiorrhiza Bunge with 5-fluorouracil on pharmacokinetics in rats and pharmacodynamics in human cells. Am J Chin Med. 2013;41:443–458. doi: 10.1142/S0192415X13500328. [DOI] [PubMed] [Google Scholar]
  • 7.Park E.Y., Kim M.H., Kim E.H., Lee E.K., Park I.S., Yang D.C., Jun H.S. Efficacy comparison of Korean ginseng and American ginseng on body temperature and metabolic parameters. Am J Chin Med. 2014;42:173–187. doi: 10.1142/S0192415X14500128. [DOI] [PubMed] [Google Scholar]
  • 8.McCarthy N. Tumorigenesis: all together now. Nat Rev Cancer. 2013;13:148–149. doi: 10.1038/nrc3469. [DOI] [PubMed] [Google Scholar]
  • 9.Lewis B., Lin J., Wu X., Xie H., Shen B., Lai K., Manilich E., Liu X. Crohn's disease-like reaction predicts favorable prognosis in colitis-associated colorectal cancer. Inflamm Bowel Dis. 2013;19:2190–2198. doi: 10.1097/MIB.0b013e31829e13e1. [DOI] [PubMed] [Google Scholar]
  • 10.Foersch S., Waldner M.J., Neurath M.F. Colitis and colorectal cancer. Dig Dis. 2012;30:469–476. doi: 10.1159/000341692. [DOI] [PubMed] [Google Scholar]
  • 11.Xiaoguang C., Hongyan L., Xiaohong L., Zhaodi F., Yan L., Lihua T., Rui H. Cancer chemopreventive and therapeutic activities of red ginseng. J Ethnopharmacol. 1998;60:71–78. doi: 10.1016/s0378-8741(97)00133-5. [DOI] [PubMed] [Google Scholar]
  • 12.Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci. 2001;16:S28–S37. doi: 10.3346/jkms.2001.16.S.S28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Qi L.W., Wang C.Z., Yuan C.S. American ginseng: potential structure-function relationship in cancer chemoprevention. Biochem Pharmacol. 2010;80:947–954. doi: 10.1016/j.bcp.2010.06.023. [DOI] [PubMed] [Google Scholar]
  • 14.Poudyal D., Le P.M., Davis T., Hofseth A.B., Chumanevich A., Chumanevich A.A., Wargovich M.J., Nagarkatti M., Nagarkatti P.S., Windust A. A hexane fraction of American ginseng suppresses mouse colitis and associated colon cancer: anti-inflammatory and proapoptotic mechanisms. Cancer Prev Res (Phila) 2012;5:685–696. doi: 10.1158/1940-6207.CAPR-11-0421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hofseth L.J., Wargovich M.J. Inflammation, cancer, and targets of ginseng. J Nutr. 2007;137:S183–S185. doi: 10.1093/jn/137.1.183S. [DOI] [PubMed] [Google Scholar]
  • 16.Zhu J., Jiang Y., Wu L., Lu T., Xu G., Liu X. Suppression of local inflammation contributes to the neuroprotective effect of ginsenoside Rb1 in rats with cerebral ischemia. Neuroscience. 2012;202:342–351. doi: 10.1016/j.neuroscience.2011.11.070. [DOI] [PubMed] [Google Scholar]
  • 17.Jin Y., Hofseth A.B., Cui X., Windust A.J., Poudyal D., Chumanevich A.A., Matesic L.E., Singh N.P., Nagarkatti M., Nagarkatti P.S. American ginseng suppresses colitis through p53-mediated apoptosis of inflammatory cells. Cancer Prev Res (Phila) 2010;3:339–347. doi: 10.1158/1940-6207.CAPR-09-0116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Benbrook D.M., Guruswamy S., Wang Y., Sun Z., Mohammed A., Zhang Y., Li Q., Rao C.V. Chemoprevention of colon and small intestinal tumorigenesis in APCmin/+ mice by SHetA2 (NSC721689) without toxicity. Cancer Prev Res (Phila) 2013;6:908–916. doi: 10.1158/1940-6207.CAPR-13-0171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Derry M.M., Raina K., Balaiya V., Jain A.K., Shrotriya S., Huber K.M., Serkova N.J., Agarwal R., Agarwal C. Grape seed extract efficacy against azoxymethane-induced colon tumorigenesis in A/J mice: interlinking miRNA with cytokine signaling and inflammation. Cancer Prev Res (Phila) 2013;6:625–633. doi: 10.1158/1940-6207.CAPR-13-0053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Khan R., Khan A.Q., Lateef A., Rehman M.U., Tahir M., Ali F., Hamiza O.O., Sultana S. Glycyrrhizic acid suppresses the development of precancerous lesions via regulating the hyperproliferation, inflammation, angiogenesis and apoptosis in the colon of Wistar rats. PLoS One. 2013;8:e56020. doi: 10.1371/journal.pone.0056020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Qi L.W., Wang C.Z., Yuan C.S. Ginsenosides from American ginseng: chemical and pharmacological diversity. Phytochemistry. 2011;72:689–699. doi: 10.1016/j.phytochem.2011.02.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Yuan C.S., Wei G., Dey L., Karrison T., Nahlik L., Maleckar S., Kasza K., Ang-Lee M., Moss J. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann Intern Med. 2004;141:23–27. doi: 10.7326/0003-4819-141-1-200407060-00011. [DOI] [PubMed] [Google Scholar]
  • 23.Christensen L.P. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res. 2009;55:1–99. doi: 10.1016/S1043-4526(08)00401-4. [DOI] [PubMed] [Google Scholar]
  • 24.Qi L.W., Wang C.Z., Yuan C.S. Isolation and analysis of ginseng: advances and challenges. Nat Prod Rep. 2011;28:467–495. doi: 10.1039/c0np00057d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Baek S.H., Bae O.N., Park J.H. Recent methodology in ginseng analysis. J Ginseng Res. 2012;36:119–134. doi: 10.5142/jgr.2012.36.2.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Wang C.Z., Du G.J., Zhang Z., Wen X.D., Calway T., Zhen Z., Musch M.W., Bissonnette M., Chang E.B., Yuan C.S. Ginsenoside compound K, not Rb1, possesses potential chemopreventive activities in human colorectal cancer. Int J Oncol. 2012;40:1970–1976. doi: 10.3892/ijo.2012.1399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Jin H.R., Zhao J., Zhang Z., Liao Y., Wang C.Z., Huang W.H., Li S.P., He T.C., Yuan C.S., Du W. The antitumor natural compound falcarindiol promotes cancer cell death by inducing endoplasmic reticulum stress. Cell Death Dis. 2012;3:e376. doi: 10.1038/cddis.2012.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Fichera A., Guo Y., Romero L., Michelassi F., Arenas R.B. Quantitation of in vivo gene delivery by restriction enzyme PCR generated polymorphism. J Surg Res. 1997;69:188–192. doi: 10.1006/jsre.1997.5073. [DOI] [PubMed] [Google Scholar]
  • 29.Paturi G., Mandimika T., Butts C.A., Zhu S., Roy N.C., McNabb W.C., Ansell J. Influence of dietary blueberry and broccoli on cecal microbiota activity and colon morphology in mdr1a–/– mice, a model of inflammatory bowel diseases. Nutrition. 2012;28:324–330. doi: 10.1016/j.nut.2011.07.018. [DOI] [PubMed] [Google Scholar]
  • 30.Mohammed A., Janakiram N.B., Li Q., Choi C.I., Zhang Y., Steele V.E., Rao C.V. Chemoprevention of colon and small intestinal tumorigenesis in APCMin/+ mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention. Cancer Prev Res (Phila) 2011;4:2015–2026. doi: 10.1158/1940-6207.CAPR-11-0233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Sun S., Qi L.W., Du G.J., Mehendale S.R., Wang C.Z., Yuan C.S. Red notoginseng: higher ginsenoside content and stronger anticancer potential than Asian and American ginseng. Food Chem. 2011;125:1299–1305. doi: 10.1016/j.foodchem.2010.10.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Qi L.W., Wang H.Y., Zhang H., Wang C.Z., Li P., Yuan C.S. Diagnostic ion filtering to characterize ginseng saponins by rapid liquid chromatography with time-of-flight mass spectrometry. J Chromatogr A. 2012;1230:93–99. doi: 10.1016/j.chroma.2012.01.079. [DOI] [PubMed] [Google Scholar]
  • 33.Wan J.Y., Liu P., Wang H.Y., Qi L.W., Wang C.Z., Li P., Yuan C.S. Biotransformation and metabolic profile of American ginseng saponins with human intestinal microflora by liquid chromatography quadrupole time-of-flight mass spectrometry. J Chromatogr A. 2013;1286:83–92. doi: 10.1016/j.chroma.2013.02.053. [DOI] [PubMed] [Google Scholar]
  • 34.Wang C.Z., Aung H.H., Ni M., Wu J.A., Tong R., Wicks S., He T.C., Yuan C.S. Red American ginseng: ginsenoside constituents and antiproliferative activities of heat-processed Panax quinquefolius roots. Planta Med. 2007;73:669–674. doi: 10.1055/s-2007-981524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Wang C.Z., Ni M., Sun S., Li X.L., He H., Mehendale S.R., Yuan C.S. Detection of adulteration of notoginseng root extract with other panax species by quantitative HPLC coupled with PCA. J Agric Food Chem. 2009;57:2363–2367. doi: 10.1021/jf803320d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Dougherty U., Mustafi R., Wang Y., Musch M.W., Wang C.Z., Konda V.J., Kulkarni A., Hart J., Dawson G., Kim K.E. American ginseng suppresses Western diet-promoted tumorigenesis in model of inflammation-associated colon cancer: role of EGFR. BMC Complement Altern Med. 2011;11:111–121. doi: 10.1186/1472-6882-11-111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Madka V., Rao C.V. Anti-inflammatory phytochemicals for chemoprevention of colon cancer. Curr Cancer Drug Targets. 2013;13:542–557. doi: 10.2174/15680096113139990036. [DOI] [PubMed] [Google Scholar]
  • 38.Garcia Rodriguez L.A., Cea-Soriano L., Tacconelli S., Patrignani P. Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. Recent Results Cancer Res. 2013;191:67–93. doi: 10.1007/978-3-642-30331-9_4. [DOI] [PubMed] [Google Scholar]
  • 39.Zhou Y., Boudreau D.M., Freedman A.N. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2014;23:43–50. doi: 10.1002/pds.3463. [DOI] [PubMed] [Google Scholar]
  • 40.Chen S., Qu X., Wan P., Li Q.W., Wang Z., Guo F., Bai L., Hu Z., Tan W., Li J. Norcantharidin inhibits pre-replicative complexes assembly of HepG2 cells. Am J Chin Med. 2013;41:665–682. doi: 10.1142/S0192415X13500468. [DOI] [PubMed] [Google Scholar]
  • 41.Liu S., Wang X.J., Liu Y., Cui Y.F. PI3K/AKT/mTOR signaling is involved in (–)-epigallocatechin-3-gallate-induced apoptosis of human pancreatic carcinoma cells. Am J Chin Med. 2013;41:629–642. doi: 10.1142/S0192415X13500444. [DOI] [PubMed] [Google Scholar]
  • 42.Wang C.Y., Bai X.Y., Wang C.H. Traditional Chinese medicine: a treasured natural resource of anticancer drug research and development. Am J Chin Med. 2014;42:543–559. doi: 10.1142/S0192415X14500359. [DOI] [PubMed] [Google Scholar]
  • 43.Park E.H., Kim Y.J., Yamabe N., Park S.H., Kim H.K., Jang H.J., Kim J.H., Cheon G.J., Ham J., Kang K.S. Stereospecific anticancer effects of ginsenoside Rg3 epimers isolated from heat-processed American ginseng on human gastric cancer cell. J Ginseng Res. 2014;38:22–27. doi: 10.1016/j.jgr.2013.11.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.De Robertis M., Massi E., Poeta M.L., Carotti S., Morini S., Cecchetelli L., Signori E., Fazio V.M. The AOM/DSS murine model for the study of colon carcinogenesis: from pathways to diagnosis and therapy studies. J Carcinog. 2011;10:9. doi: 10.4103/1477-3163.78279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Wen X.D., Wang C.Z., Yu C., Zhang Z., Calway T., Wang Y., Li P., Yuan C.S. Salvia miltiorrhiza (dan shen) significantly ameliorates colon inflammation in dextran sulfate sodium induced colitis. Am J Chin Med. 2013;41:1097–1108. doi: 10.1142/S0192415X13500742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Day S.D., Enos R.T., McClellan J.L., Steiner J.L., Velázquez K.T., Murphy E.A. Linking inflammation to tumorigenesis in a mouse model of high-fat-diet-enhanced colon cancer. Cytokine. 2013;64:454–462. doi: 10.1016/j.cyto.2013.04.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Jacoby R.F., Seibert K., Cole C.E., Kelloff G., Lubet R.A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 2000;60:5040–5044. [PubMed] [Google Scholar]
  • 48.Yuan C.S., Wang C.Z., Wicks S.M., Qi L.W. Chemical and pharmacological studies of saponins with a focus on American ginseng. J Ginseng Res. 2010;34:160–167. doi: 10.5142/jgr.2010.34.3.160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Tawab M.A., Bahr U., Karas M., Wurglics M., Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos. 2003;31:1065–1071. doi: 10.1124/dmd.31.8.1065. [DOI] [PubMed] [Google Scholar]
  • 50.Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci. 2004;95:153–157. doi: 10.1254/jphs.fmj04001x4. [DOI] [PubMed] [Google Scholar]
  • 51.Oh G.S., Pae H.O., Choi B.M., Seo E.A., Kim D.H., Shin M.K., Kim J.D., Kim J.B., Chung H.T. 20(S)-Protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions through inactivation of nuclear factor-kappaB in RAW 264.7 macrophages stimulated with lipopolysaccharide. Cancer Lett. 2004;205:23–29. doi: 10.1016/j.canlet.2003.09.037. [DOI] [PubMed] [Google Scholar]
  • 52.Punja Z.K. American ginseng: research developments, opportunities, and challenges. J Ginseng Res. 2011;35:368–374. doi: 10.5142/jgr.2011.35.3.368. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Ginseng Research are provided here courtesy of Elsevier

RESOURCES